Alnylam Pharmaceuticals (ALNY) 10-Q2012 Q1 Quarterly report

Filed: 3 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accrual, addressed, Avenue, BLA, clotting, compensatory, Concord, conversion, differentiation, disgorgement, disorder, dispositive, distract, dominating, dropping, easier, enjoining, enzyme, exemption, expert, expressly, feet, frame, group, HDL, highest, hire, input, juncture, knockdown, lease, leasing, length, lipoprotein, LLC, located, lowest, mediation, Meltemi, mild, move, multinational, Park, pendency, phenotype, Pond, postmarketing, potency, punitive, question, rash, real, recurrent, regimen, remote, reply, requested, restated, robust, shown, sickle, space, square, standing, statistically, streamline, stringent, subcutaneously, substance, suit, tendency, transient, transition, understand, underwriting, underwritten

Removed: ACD, adjust, aim, allocating, began, biopsy, Biotech, blinded, BOS, central, chronic, circulating, Code, complication, comprising, computed, consulting, coordinated, customer, declined, demonstration, description, designate, developin, disappointing, discrete, dismissal, diversify, effected, eliminating, endothelial, endpoint, equipment, escalation, evaluable, expire, factor, family, France, hepcidin, immune, implanted, incidence, incorporating, inhibition, innovative, integrate, integration, iron, kinesin, KSP, label, leadership, led, mechanism, open, partly, Portugal, predominant, prejudice, professional, progressive, ratio, realization, receivable, reclassified, refund, reliable, renal, residual, resolving, return, role, running, scheduled, separating, short, solid, spindle, standalone, Stanford, subjective, substantive, surviving, Sweden, syndrome, therapy, urine, utilization, validated, vascular, VEGF, vendor, vivoRNAi

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ALNY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12

STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS/DEFICIENCIES TO FIXED CHARGES

(dollars in thousands)


	Three Months ended March 31, 2012			Fiscal Year Ended December 31,
	Three Months ended March 31, 2012			2011			2010			2009			2008			2007
Earnings (loss):
Pre-tax loss from continuing operations before adjustment for loss from equity investee	$	(10,479	)	$	(54,144	)	$	(35,362	)	$	(42,098	)	$	(16,240	)	$	(79,146	)
add: Fixed charges (see below)		285			1,207			1,207			712			1,115			1,553

Pre-tax income (loss) from continuing operations before adjustment for income/loss from equity investees plus fixed charges	$	(10,194	)	$	(52,937	)	$	(34,155	)	$	(41,386	)	$	(15,125	)	$	(77,593	)

Fixed charges:
Interest expense on indebtedness	$	—		$	—		$	—		$	—		$	872		$	1,083
Interest expense on portion of rent expense representative of interest		285			1,207			1,207			712			243			470

Total fixed charges	$	285		$	1,207		$	1,207		$	712		$	1,115		$	1,553

Ratio of earnings to fixed charges		—			—			—			—			—			—

Deficiency of earnings available to cover fixed charges	$	(10,479	)	$	(54,144	)	$	(35,362	)	$	(42,098	)	$	(16,240	)	$	(79,146	)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.